Ovarian Cancer Trial, Recruiting (NCT05129969)

Ovarian Cancer Trial, Recruiting NCT05129969 Sponsor: iOMEDICO AG Condition: Ovarian Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT05129969 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Ovarian Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with high-grade ovarian, fallopian tube, or primary peritoneal cancer at an advanced or widespread stage (stage IIb or higher), and you are about to start a new course of treatment.
Your ovarian, fallopian tube, or primary peritoneal cancer has come back after previous treatment, and you are about to start a new course of treatment for this recurrence.
You have advanced or inoperable uterine (womb) cancer at stage III or IV, and you are about to begin your first course of treatment.
You are willing and able to sign a consent form — if taking part in the patient-reported experience part of the study, this must be signed before your first treatment; otherwise, it can be signed up to six weeks after starting treatment.

Who may not be able to join:

You have newly diagnosed ovarian cancer that is at an early stage (stage I or IIa).
You have a slower-growing (low-grade) form of ovarian cancer that has spread (confirm with trial site).
You have uterine (womb) cancer that is at an early stage (stage I or II).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 9 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Thomas Decker, Prof.Dr., Ravensburg

Phone: +49 761 15242-0

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05129969

Sponsor: iOMEDICO AG

Phase: Not Applicable

Status: Recruiting

Condition: Ovarian Cancer

Trial contact: +49 761 15242-0

More information: https://clinicaltrials.gov/study/NCT05129969

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with high-grade ovarian, fallopian tube, or primary peritoneal cancer at an advanced or widespread stage (stage IIb or higher), and you are about to start a new course of treatment.
Your ovarian, fallopian tube, or primary peritoneal cancer has come back after previous treatment, and you are about to start a new course of treatment for this recurrence.
You have advanced or inoperable uterine (womb) cancer at stage III or IV, and you are about to begin your first course of treatment.
You are willing and able to sign a consent form — if taking part in the patient-reported experience part of the study, this must be signed before your first treatment; otherwise, it can be signed up to six weeks after starting treatment.

Who may not be able to join:

You have newly diagnosed ovarian cancer that is at an early stage (stage I or IIa).
You have a slower-growing (low-grade) form of ovarian cancer that has spread (confirm with trial site).
You have uterine (womb) cancer that is at an early stage (stage I or II).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 9 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

iOMEDICO AG

Registry

ClinicalTrials.gov

Start date

25 November 2021

Est. completion

1 December 2030

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Course of treatment (treatment reality).

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov